Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors

Introduction: In- and exclusion criteria of randomized clinical trials (RCTs) aim to include a homogeneous study-population. This study compared characteristics of lung cancer patients from phase III RCTs evaluating tyrosine kinase inhibitors (TKIs) or immune checkpoint inhibitors (ICIs) with charac...

Full description

Bibliographic Details
Main Authors: Abtahi, S. (Author), Croes, S. (Author), de Vries, F. (Author), Dingemans, A.-M.C (Author), Driessen, J.H.M (Author), Klungel, O.H (Author), Souverein, P. (Author), van Geel, R. (Author), van Veelen, A. (Author)
Format: Article
Language:English
Published: Elsevier Ltd 2022
Subjects:
CPRD
Immune checkpoint inhibitors
Lung cancer
Study eligibility
Tyrosine kinase inhibitors
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items